2005
Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study
Modi W, Scott K, Goedert J, Vlahov D, Buchbinder S, Detels R, Donfield S, O'Brien S, Winkler C. Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study. Genes & Immunity 2005, 6: 691-698. PMID: 16177829, DOI: 10.1038/sj.gene.6364258.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdolescentAdultAllelesBlack or African AmericanChemokine CXCL12Chemokines, CXCChildCohort StudiesDisease ProgressionFemaleGene FrequencyHaplotypesHIV InfectionsHIV-1HumansLongitudinal StudiesMaleOdds RatioPolymorphism, Single NucleotideRisk FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsSDF-1 geneCohort studySingle nucleotide polymorphismsAfrican AmericansOnly natural ligandSingle disease outcomesX4 HIV-1HIV-1 infectionAIDS Cohort StudyRisk of infectionMACS cohortDisease outcomeHIV-1Epidemiological studiesSDF-1Significant associationChemokine genesInfectionRs1801157Natural ligandProgressionHaplotype analysisCommon haplotypeCXCR4Cohort
2003
Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans
Duggal P, An P, Beaty T, Strathdee S, Farzadegan H, Markham R, Johnson L, O'Brien S, Vlahov D, Winkler C. Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes & Immunity 2003, 4: 245-250. PMID: 12761559, DOI: 10.1038/sj.gene.6363950.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaLate-stage HIV-1 infectionAfrican AmericansHIV-1 infectionMedian survival timeSIV infectionCarinii pneumoniaChemokine receptorsAIDS progressionPrimary coreceptorSurvival timeK polymorphismInitial infectionCXCR6Receptor allelesInfectionProgressionSingle nucleotide polymorphismsDeathK genotypesAIDSCoreceptorNucleotide polymorphismsGenetic influencesAllele frequenciesEffects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression
Mulherin S, O'Brien T, Ioannidis J, Goedert J, Buchbinder S, Coutinho R, Jamieson B, Meyer L, Michael N, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Theodorou I, Vlahov D, Rosenberg P. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression. AIDS 2003, 17: 377-387. PMID: 12556692, DOI: 10.1097/00002030-200302140-00012.Peer-Reviewed Original ResearchConceptsHIV-1 disease progressionHIV-1 seroconvertersCCR5-Delta32CCR2-64ICourse of infectionDisease progressionLower riskChemokine receptor gene polymorphismsCox proportional hazards modelHIV-1 infectionIndividual patient dataCCR2-64I alleleProportional hazards modelReceptor gene polymorphismsCCR2-64I.Disease courseSurvival benefitHazards modelGene polymorphismsCCR5-Δ32Significant protectionAIDSPatient dataInfectionSeroconverters
2001
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.
Ioannidis J, Rosenberg P, Goedert J, Ashton L, Benfield T, Buchbinder S, Coutinho R, Eugen-Olsen J, Gallart T, Katzenstein T, Kostrikis L, Kuipers H, Louie L, Mallal S, Margolick J, Martinez O, Meyer L, Michael N, Operskalski E, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Stewart G, Theodorou I, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury J, O'Brien T. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Annals Of Internal Medicine 2001, 135: 782-95. PMID: 11694103, DOI: 10.7326/0003-4819-135-9-200111060-00008.Peer-Reviewed Original ResearchConceptsHIV-1 infectionCCR2-64I alleleHIV-1 RNA levelsHIV-1 disease progressionDevelopment of AIDSIndividual patient dataCCR5-Delta32Decreased riskDisease progressionProtective effectLower HIV-1 RNA levelsRNA levelsProspective cohort studyCase-control studyClear protective effectStrong protective effectChemokine receptor genesRandom-effects modelCCR2-64ICohort studyStudy entryCertain chemokinesAIDSInfectionProgressionIsoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis
Sadaphal P, Astemborski J, Graham N, Sheely L, Bonds M, Madison A, Vlahov D, Thomas D, Sterling T. Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis. Clinical Infectious Diseases 2001, 33: 1687-1691. PMID: 11641824, PMCID: PMC2650436, DOI: 10.1086/323896.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersTuberculosis infectionValue elevationDrug usersCurrent injection drug useLatent Mycobacterium tuberculosis infectionHepatitis C virus infectionHepatitis B surface antigenLow HCV prevalenceC virus infectionIsoniazid preventive therapyInjection drug useM. tuberculosis infectionMycobacterium tuberculosis infectionHIV-1 infectionHuman immunodeficiency virusB surface antigenConcurrent alcohol useDrug discontinuationHCV prevalencePreventive therapyImmunodeficiency virusProspective studyTransaminase valuesEffect of a Single Amino Acid Change in MHC Class I Molecules on the Rate of Progression to AIDS
Gao X, Nelson G, Karacki P, Martin M, Phair J, Kaslow R, Goedert J, Buchbinder S, Hoots K, Vlahov D, O'Brien S, Carrington M. Effect of a Single Amino Acid Change in MHC Class I Molecules on the Rate of Progression to AIDS. New England Journal Of Medicine 2001, 344: 1668-1675. PMID: 11386265, DOI: 10.1056/nejm200105313442203.Peer-Reviewed Original ResearchConceptsRate of progressionHIV-1 infectionClass IHuman immunodeficiency virus type 1 (HIV-1) infectionDifferent peptide-binding specificitiesVirus type 1 infectionRisk of progressionT lymphocyte responsesInfluence of HLAType 1 infectionHIV-1 epitopesSubtypes of HLAHLA class IPeptide-binding specificityMHC class I moleculesAmino acid changesComplex class ISingle amino acid changeClass I moleculesReactive HLAImmunodeficiency syndromeRelated HLAPx groupCommon HLAHIV-1Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men
Sterling T, Vlahov D, Astemborski J, Hoover D, Margolick J, Quinn T. Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal Of Medicine 2001, 344: 720-725. PMID: 11236775, DOI: 10.1056/nejm200103083441003.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD4 Lymphocyte CountDisease ProgressionDisease-Free SurvivalEligibility DeterminationFemaleHIV AntibodiesHIV InfectionsHIV-1HumansLongitudinal StudiesMalePractice Guidelines as TopicRegression AnalysisReverse Transcriptase Polymerase Chain ReactionRiskRNA, ViralSex FactorsViral LoadConceptsInitial viral loadMedian initial viral loadHIV-1 RNAViral loadLymphocyte countHuman immunodeficiency virus type 1 (HIV-1) infectionPlasma HIV-1 RNA levelsHIV-1 RNA levelsHIV-1 RNA copiesFemale injection drug usersVirus type 1 infectionHIV-1 seroconversionMedian initial CD4Risk of progressionHIV-1 infectionType 1 infectionInjection drug usersLikelihood of progressionRate of progressionAntiretroviral therapyInitial CD4Hazard ratioAntiretroviral treatmentTreatment guidelinesImmunodeficiency syndrome
2000
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10
Shin H, Winkler C, Stephens J, Bream J, Young H, Goedert J, O'Brien T, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, O'Brien S, Smith M. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 14467-14472. PMID: 11121048, PMCID: PMC18942, DOI: 10.1073/pnas.97.26.14467.Peer-Reviewed Original ResearchConceptsHIV-1 infectionHIV-1 replicationTranscription factor recognition sequencePromoter allelesLong-term nonprogressorsHIV-1 pathogenesisSingle nucleotide polymorphic variantsOnset of AIDSMacrophages/monocytesNuclear transcription factorSignificant genotype associationsIL10 promoter regionShort tandem repeat polymorphismsTranscription factorsPromoter regionRecognition sequenceIL10 productionInflammatory cytokinesCell cytokinesAIDS cohortC genotypeLymphoid cellsPromoter genotypeGenetic restrictionLymphocyte replication
1998
Genetic Acceleration of AIDS Progression by a Promoter Variant of CCR5
Martin M, Dean M, Smith M, Winkler C, Gerrard B, Michael N, Lee B, Doms R, Margolick J, Buchbinder S, Goedert J, O'Brien T, Hilgartner M, Vlahov D, O'Brien S, Carrington M. Genetic Acceleration of AIDS Progression by a Promoter Variant of CCR5. Science 1998, 282: 1907-1911. PMID: 9836644, DOI: 10.1126/science.282.5395.1907.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAllelesChemokine CXCL12Chemokines, CXCCohort StudiesDisease ProgressionGenes, DominantGenes, RecessiveGenetic Predisposition to DiseaseGenotypeHaplotypesHeterozygoteHIV InfectionsHIV-1HomozygoteHumansPromoter Regions, GeneticProportional Hazards ModelsReceptors, CCR2Receptors, CCR5Receptors, ChemokineReceptors, CytokineRisk FactorsSurvival RateConceptsAIDS progressionCell-surface chemokine receptor moleculeCCR5 regulatory regionsChemokine receptor moleculesPercent of patientsAIDS disease progressionHIV-1 infectionCohort of peopleMacrophage-tropic strainsAIDS restriction genesDistinct regulatory influencesCCR2-64IPrincipal coreceptorImmunodeficiency syndromeCCR5-Delta32Genetic epidemiologic analysisDisease progressionHuman immunodeficiencySDF1-3'APromoter genotypeCCR5 geneInfected individualsEpidemiologic analysisHost factorsProgressionDiversification of Subtype E Human Immunodeficiency Virus Type 1 env in Heterosexual Seroconverters from Northern Thailand
Wang Z, Lyles C, Beyrer C, Celentano D, Vlahov D, Natpratan C, Markham R, Khamboonruang C, Nelson K, Yu X. Diversification of Subtype E Human Immunodeficiency Virus Type 1 env in Heterosexual Seroconverters from Northern Thailand. The Journal Of Infectious Diseases 1998, 178: 1507-1511. PMID: 9780276, DOI: 10.1086/314441.Peer-Reviewed Original ResearchConceptsHIV-1 infectionAsymptomatic HIV-1-infected subjectsHIV-1 subtype EHIV-1-infected subjectsHuman Immunodeficiency Virus Type 1 EnvSubtype E HIVC2-V3 regionHuman immunodeficiency virusHIV vaccine developmentInjection drug usersE HIVRecent seroconvertersImmunodeficiency virusSubtype ESeroconvertersHIV-1Drug usersVaccine developmentMolecular epidemiologyEnv sequencesInfectionEnvNorthern ThailandHIVBaltimoreOpiates as potential cofactors in progression of HIV-1 infections to AIDS
Donahoe R, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. Journal Of Neuroimmunology 1998, 83: 77-87. PMID: 9610676, DOI: 10.1016/s0165-5728(97)00224-5.Peer-Reviewed Original ResearchConceptsHIV-1 infectionEffects of opiatesOpiate useAIDS progressionEpidemiological studiesImmune processesCD4 T-cell countT-cell countsHIV-1 expressionHost protective responsesAssociation of AIDSOpiate exposureOpportunistic infectionsAIDS pathogenesisHIV-1Monkey modelOpiate abuseEpidemiological dataInfectious processClinical observationsProtective responseOpiatesInfectionAIDSDrug abuse
1997
Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression
Smith M, Dean M, Carrington M, Winkler C, Huttley G, Lomb D, Goedert J, O'Brien T, Jacobson L, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner M, Study H, San Francisco City Cohort ALIVE Study M, O'Brien S. Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression. Science 1997, 277: 959-965. PMID: 9252328, DOI: 10.1126/science.277.5328.959.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBlack PeopleCohort StudiesDisease ProgressionGenotypeHaplotypesHeterozygoteHIV InfectionsHIV-1HumansMutationPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPolymorphism, Single-Stranded ConformationalProportional Hazards ModelsReceptors, CCR2Receptors, CCR5Receptors, ChemokineReceptors, CytokineReceptors, HIVSurvival AnalysisWhite PeopleConceptsHIV-1 infectionCCR2-64IDisease progressionHIV-1 disease progressionHIV-1-infected individualsLong-term survivorsCCR2-64I alleleReceptor geneChemokine receptor genesAIDS 2CCR2 chemokineSyndrome cohortAIDS patientsCCR5-Delta32Human immunodeficiencyChemokine receptorsCCR5 variantsCCR2CCR5InfectionIndependent effectsAfrican AmericansMutant genotypesProgressionGenetic association analysis
1996
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene
Dean M, Carrington M, Winkler C, Huttley G, Smith M, Allikmets R, Goedert J, Buchbinder S, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien S. Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene. Science 1996, 273: 1856-1862. PMID: 8791590, DOI: 10.1126/science.273.5283.1856.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBase SequenceChromosome MappingChromosomes, Human, Pair 3Cohort StudiesDisease ProgressionGenesHemophilia AHeterozygoteHIV InfectionsHIV-1Homosexuality, MaleHomozygoteHumansImmunity, InnateMaleMolecular Sequence DataReceptors, CCR5Receptors, CytokineReceptors, HIVRisk FactorsSequence DeletionSurvival AnalysisConceptsHIV-1 infectionHIV-1-infected individualsAntibody-negative individualsCohort studyRapid progressorsHuman immunodeficiencyDisease progressionRisk groupsT lymphocytesGenetic restrictionSurvival analysisInfected individualsDeletion alleleCaucasian populationInfectionAIDSProgressionHuman chromosome 3p21Secondary receptorGroup of individualsChromosome 3p21Certain strainsDeletion homozygotesIndividualsProgressorsAlcohol Use and T‐Lymphocyte Subsets among Injection Drug Users with HIV‐1 Infection: A Prospective Analysis
Crum R, Galai N, Cohn S, Celentano D, Vlahov D. Alcohol Use and T‐Lymphocyte Subsets among Injection Drug Users with HIV‐1 Infection: A Prospective Analysis. Alcohol Clinical And Experimental Research 1996, 20: 364-371. PMID: 8730231, DOI: 10.1111/j.1530-0277.1996.tb01654.x.Peer-Reviewed Original ResearchConceptsInjection drug usersCohort of IDUsT lymphocyte subsetsDrinks/weekHIV seroconversionAlcohol useYears postseroconversionDrug usersAlcohol categoriesHIV-positive injection drug usersCD8 absolute countsHIV-1 seroconvertersProgression of immunodeficiencyLevels of CD4Intravenous drug useT lymphocyte subpopulationsFirst prospective studyHIV-1 infectionTime of seroconversionSignificant differencesEarly intervention programsHIV infectionHIV progressionOutpatient clinicProspective studyIncidence and risk factors for HIV-1 infection—a summary of what is known and the psychiatric relevance
Hoover D, Doherty M, Vlahov D, Miotti P. Incidence and risk factors for HIV-1 infection—a summary of what is known and the psychiatric relevance. International Review Of Psychiatry 1996, 8: 137-148. DOI: 10.3109/09540269609046298.Peer-Reviewed Original ResearchInjection drug useHIV-1 transmissionInfected mothersHuman immunodeficiency virus type 1 (HIV-1) epidemicDrug useSexual HIV-1 transmissionGreatest killerHIV-1 diseaseRisky drug useHIV-1 infectionType 1 epidemicHIV-1 epidemicRisk of infectionRisk of transmissionUse of condomsZidovudine therapyInfected partnerBreast feedingRisk factorsRisk groupsClean needlesHIV-1AIDS casesInfected personsHomosexual men
1993
Increased Mortality Associated With Vitamin A Deficiency During Human Immunodeficiency Virus Type 1 Infection
Semba R, Graham N, Caiaffa W, Margolick J, Clement L, Vlahov D. Increased Mortality Associated With Vitamin A Deficiency During Human Immunodeficiency Virus Type 1 Infection. JAMA Internal Medicine 1993, 153: 2149-2154. PMID: 8379807, DOI: 10.1001/archinte.1993.00410180103012.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 (HIV-1) infectionHIV-1-seropositive individualsVirus type 1 infectionCD4 T cellsHIV-1 infectionType 1 infectionPlasma vitaminT cellsHIV-1-seronegative individualsMean plasma vitaminLow CD4 levelsIntravenous drug usersHIV-seropositive participantsBlood cell countImportant risk factorNormal immune functionMumol/LCD4 levelsSeronegative individualsImmunologic statusSerologic markersClinical outcomesLiver diseaseSeropositive individualsIncreased MortalityComparison of Clinical Symptoms of Human Immunodeficiency Virus Disease Between Intravenous Drug Users and Homosexual Men
Palenicek J, Nelson K, Vlahov D, Galai N, Cohn S, Saah A. Comparison of Clinical Symptoms of Human Immunodeficiency Virus Disease Between Intravenous Drug Users and Homosexual Men. JAMA Internal Medicine 1993, 153: 1806-1812. PMID: 8101438, DOI: 10.1001/archinte.1993.00410150094009.Peer-Reviewed Original ResearchConceptsIntravenous drug usersCD4 cell levelsClinical symptomsDrug usersHomosexual menOral candidiasisHIV infectionPhysical examinationRisk groupsMale intravenous drug usersHuman immunodeficiency virus (HIV) diseaseRisk behavior interviewsCD4 cell countTotal lymphocyte countIntravenous drug useShortness of breathMost clinical symptomsHIV-1 infectionHuman immunodeficiency virusFrequency of symptomsIntermediate outcome measuresCell levelAbnormal hematocritHIV immunosuppressionNight sweatsDetection of Human Immunodeficiency Virus Type 1 Infection by Polymerase Chain Reaction in a Cohort of Seronegative Intravenous Drug Users
Farzadegan H, Vlahov D, Solomon L, Muñoz A, Astemborski J, Taylor E, Burnley A, Nelson K. Detection of Human Immunodeficiency Virus Type 1 Infection by Polymerase Chain Reaction in a Cohort of Seronegative Intravenous Drug Users. The Journal Of Infectious Diseases 1993, 168: 327-331. PMID: 8335969, DOI: 10.1093/infdis/168.2.327.Peer-Reviewed Original ResearchConceptsSeronegative intravenous drug usersIntravenous drug usersHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionType 1 infectionPolymerase chain reactionDrug usersHIV-1 infectionHIV-1 antibodiesChain reactionLarge cohortBlood specimensProviral DNAInfectionCohortPCR analysisPersonsSerologyFollowVisitsAntibodiesMonthsElevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users
Strickler H, Blanchard J, Vlahov D, Taylor E, Muñoz A, Nelson K, Margolick J. Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users. AIDS 1993, 7: 361-368. PMID: 8471199, DOI: 10.1097/00002030-199303000-00009.Peer-Reviewed Original ResearchConceptsDrug useNeopterin levelsSerum levelsDrug usersSerum beta 2MBeta 2M levelsSerum beta 2M levelsMean neopterin levelsSerum neopterin levelsElevated serum levelsHIV-1 infectionCellular immune activationBeta 2MRisk factor variablesIntravenous Experience (ALIVE) studyM levelsMale IDUsSerum neopterinImmune activationProspective studyImmunocompetent cellsHIV-1Β2-microglobulinConsecutive daysNeopterin
1992
HIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects.
Selnes O, McArthur J, Royal W, Updike M, Nance-Sproson T, Concha M, Gordon B, Solomon L, Vlahov D. HIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects. Neurology 1992, 42: 1924-30. PMID: 1407574, DOI: 10.1212/wnl.42.10.1924.Peer-Reviewed Original ResearchConceptsIntravenous drug usersIntravenous drug useDrug usersHIV infectionSerostatus groupsHIV-seropositive intravenous drug usersDrug useHIV-1 infectionHigh-risk groupRoute of acquisitionLongitudinal neuropsychological evaluationCross-sectional comparisonPreexisting deficitAsymptomatic subjectsLongitudinal followAdditional cognitive impairmentPresymptomatic stageNeurocognitive abnormalitiesCognitive impairmentNeuropsychological evaluationNeuropsychological deficitsSame cohortBisexual menInfectionSignificant differences